A Phase 3 interventional study of inebilizumab and IV Placebo in Myasthenia Gravis, sponsored by Amgen. Active, not recruiting at 104 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 73 under way, 25 of them phase 3. Myasthenia Gravis · United States.
Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 4th largest by enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2020, is one of 45 in phase 3, reaches primary completion later than 2 of the 72 other live ones, and was the 55th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
George Washington University · Sites in United States
Ages 18+
Amgen · Sites in United States, Argentina, Brazil and 5 more countries
Ages 2–17
argenx · Sites in United States, Belgium, Greece and 4 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
144 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 38 · Phase 3 51 · Phase 4 3
First in 1995; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 238 is above the median of 44 across 217 interventional studies indexed under Myasthenia Gravis.
Median enrollment 56 across the 108 interventional studies, 226 across the 36 observational. Of the 64 that completed or were terminated, 41 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
96 of 144 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 2 studies filed under Myasthenia Gravis — fewer than ten, so there is no comparison to draw.
18 of the studies in Myasthenia Gravis with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06607627Phase 3Alexion Pharmaceuticals, Inc.PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis | 2026-12-15 |
| NCT06799247Phase 3Cartesian TherapeuticsInvestigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | 2026-12-30 |
| NCT04833894Phase 3argenxEvaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis | 2027-03 |
| NCT06456580Phase 3Vor BiopharmaA Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | 2027-03 |
| NCT06517758Phase 3Novartis PharmaceuticalsA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | 2027-04-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 144 studies in Myasthenia Gravis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
This study is a phase 3, randomized, double-blind, placebo-controlled study, to be conducted at approximately 120 study sites. Approximately 230 participants (188 acetylcholine receptor antibody positive [AChR-Ab+] and 42 muscle-specific tyrosine kinase antibody positive [MuSK-Ab+]) will be enrolled. Participants with Myasthenia Gravis (MG) who are positive for anti-AChR or anti-MuSK antibodies will be enrolled and analyzed. Patients who do not have anti-AChR or anti-MuSK antibodies will not be enrolled. Patients with Myasthenia Gravis Foundation of America (MGFA) classification II, III, or IV disease, Myasthenia Gravis Activities of Daily Living (MG-ADL) score at screening and randomization between 6 and 10 with > 50% of this score attributed to non-ocular items, or an MG-ADL score >=11, Quantitative Myasthenia Gravis (QMG) score >= 11 at the time of screening and randomization, and use of a corticosteroid and/or non-steroidal immunosuppressant will be included in the study.
All subjects who complete the randomized controlled period (RCP) will have the option to enroll in a 3-year (156 weeks) open-label period.
Study acquired from Horizon in 2023.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must be on:
Allowed ISTs, alone or in combination with corticosteroids, are azathioprine, mycophenolate mofetil, and mycophenolic acid.
Exclusion Criteria:
Receipt of the following medications within the 4 weeks prior to Day 1:
Current use of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the RCP. Participants who elect to enter the open label phase (OLP) will receive inebilizumab administered IV on OLP Days 1, IV placebo on OLP Day 15 (to avoid potential unblinding), and inebilizumab IV on OLP Days 183, 365, 547, 729, and 911.
Drug: inebilizumab
Participants will receive placebo administered IV on Days 1, 15, and 183 of the RCP. Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Days 1,15, 183, 365, 547, 729, and 911.
Drug: IV Placebo
Participants will receive inebilizumab administered IV on Days 1 and 15 of the RCP. Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Day 1, IV placebo on OLP Day 15 (to avoid potential unblinding), and inebilizumab IV on OLP Days 183, 365, 547, 729, and 911.
Drug: inebilizumab
Participants will receive placebo administered IV on Days 1 and 15 of the RCP. Participants who elect to enter the OLP will receive inebilizumab administered IV on OLP Days 1,15, 183, 365, 547, 729, and 911.
Drug: IV Placebo
Participants will receive IV inebilizumab
Also known as: MEDI-551, VIB0551
Participants will receive IV placebo matched to inebilizumab
Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease Outcome measure is reported for the overall population.
Time frame: Baseline and Week 26
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score at Week 26 in the Overall Study Population
The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the overall population.
Time frame: Baseline and Week 26
Change From Baseline at Week 26 in MG-ADL Score in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Baseline and Week 26
Change From Baseline in QMG Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Baseline and Week 26
Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in the Overall Study Population
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included intravenous immunoglobulin (IVIg) and therapeutic plasma exchange (PLEX). Outcome measure is reported for the overall population.
Time frame: Up to Week 26
Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included IVIg and PLEX. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Up to Week 26
Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 52 and no Use of Rescue Therapy Between Day 28 and Week 52 in Anti-AChR-Ab+ Population
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included IVIg and PLEX. Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: Up to Week 52
Percentage of Participants With no Use of Rescue Therapy Between Day 28 and Week 52 in Anti-AChR-Ab+ Population
The protocol-allowed rescue therapy options included corticosteroids, IVIg and PLEX. Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: Up to Week 52
Change From Baseline in MG-ADL Score at Week 52 in the Anti-AChR-Ab+ Population
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: Baseline and Week 52
Change From Baseline in QMG Score at Week 52 in the Anti-AChR-Ab+ Population
The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: Baseline and Week 52
Change From Baseline in Myasthenia Gravis Composite (MGC) Score at Week 26 in the Overall Study Population
The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the overall population.
Time frame: Baseline and Week 26
Change From Baseline in MGC Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Baseline and Week 26
Change From Baseline in MGC Score at Week 52 in Anti-AChR-Ab+ Population
The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: Baseline and Week 52
Change From Baseline in Myasthenia Gravis Quality of Life-15, Revised (MGQOL-15r) Score at Week 26 in the Overall Study Population
MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome measure is reported for the overall population.
Time frame: Baseline and Week 26
Change From Baseline in MGQOL-15r Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Baseline and Week 26
Change From Baseline in MGQOL-15r Score at Week 52 in Anti-AChR-Ab+ Population
MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome Measure is reported for the Anti-AChR-Ab+ population.
Time frame: Baseline and Week 52
Percentage of Participants With Patient Global Impression of Change (PGIC) Scores at Week 26 in the Overall Study Population
The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. Participant rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse", Outcome measure is reported for the overall population.
Time frame: Week 26
Percentage of Participants With PGIC Scores at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. Participants rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse". Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Week 26
Percentage of Participants With PGIC Scores at Week 52 in Anti-AChR-Ab+ Population
The self-report measure PGIC score reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. participants rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse". Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: Week 52
Percentage of Participants Experiencing Exacerbation by Week 26 in the Overall Study Population
An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the overall population.
Time frame: Up to Week 26
Percentage of Participants Experiencing Exacerbation by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Up to Week 26
Percentage of Participants Experiencing Exacerbation by Week 52 in Anti-AChR-Ab+ Population
An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: Up to Week 52
Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 26
MSE was defined as MG-ADL= 0 or 1. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK+ populations.
Time frame: From Day 28 to Week 26
Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in the Overall Study Population
Outcome measure is reported for the overall population.
Time frame: Week 26
Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Week 26
Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 52 in Anti-AChR-Ab+ Population
Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: Week 52
Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population
Outcome measure is reported for the overall population.
Time frame: Week 26
Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Week 26
Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 52 in the Anti-AChR-Ab+ Population
Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: Week 52
Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), AE of Special Interest (AESIs) and Serious TEAEs (SAEs).
An AE is any untoward medical occurrence associated with the use of the IP, whether or not it is considered related. Clinically significant changes from baseline in clinical laboratory results, vital signs and ECGs were also reported as AEs. An AESI is an event of medical interest specific to the understanding of the IP and which may require close monitoring and collection of additional information. A SAE is considered "serious" if it results in any of the following outcomes: * Death; * A life-threatening AE. An event is considered "life-threatening" if its occurrence places the patient or subject at immediate risk of death; * Inpatient hospitalization or prolongation of existing hospitalization; * A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; * A congenital anomaly/birth defect; * May require medical or surgical intervention to prevent one of the outcomes listed in this definition.
Time frame: For RCP AE reporting: from Day 1 to the end of RCP or cutoff date (up to 65.4 weeks)
Percentage of Participants With Anti-drug Antibodies (ADA) by Week 26 in the Overall Study Population
Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported for the overall population.
Time frame: From Baseline to Week 26
Percentage of Participants With ADA by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: From Baseline to Week 26
Percentage of Participants With ADA by Week 52 in Anti-AChR-Ab+ Population
Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported for the Anti-AChR-Ab+ population.
Time frame: From Baseline to Week 52
Time to Maximum Serum Concentration (Tmax) of Inebilizumab in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
On inebilizumab dosing days, inebilizumab pharmacokinetic (PK) serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Days 1 and 15 for Anti-MuSK-Ab+ population; Days 1, 15 and 183 (Week 26) for Anti-AChR-Ab+ population
Maximum Observed Serum Concentration (Cmax) of Inebilizumab in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations
On inebilizumab dosing days, inebilizumab PK serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Days 1 and 15 for Anti-MuSK-Ab+ population; Days 1, 15 and 183 (Week 26) for Anti-AChR-Ab+ population
Area Under the Serum Concentration Time Curve of the Dosing Interval (AUC0-14d) of Inebilizumab
On inebilizumab dosing days, inebilizumab PK serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
Time frame: Days 1 and 15 for Anti-MuSK-Ab+ population; Days 1, 15 and 183 (Week 26) for Anti-AChR-Ab+ population
A total of 238 participants were enrolled in 18 countries, from 15 October 2020. This study is ongoing. Data cut-off date for primary analysis was 28 May 2024.
| Milestone | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Started | 95 | 95 | 24 | 24 |
| Completed | 68 | 75 | 23 | 24 |
| Not completed | 27 | 20 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Death | 2 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 2 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 2 | 1 | 0 |
| Withdrew: Miscellaneous | 1 | 0 | 0 | 0 |
| Withdrew: Ongoing at primary analysis data cut-off | 14 | 15 | 0 | 0 |
| Milestone | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Started | 62 | 70 | 22 | 24 |
| Completed | 1 | 1 | 0 | 3 |
| Not completed | 61 | 69 | 22 | 21 |
| Withdrew: Ongoing at primary analysis data cut-off | 48 | 58 | 15 | 10 |
| Withdrew: Miscellaneous | 8 | 6 | 5 | 5 |
| Withdrew: Withdrawal by subject | 3 | 3 | 1 | 5 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 0 |
The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the overall population.
| Score on a scale | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score at Week 26 in the Overall Study Population | -2.3 (-3.4 to -1.3) | -4.8 (-5.8 to -3.8) |
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Score on a scale | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Change From Baseline at Week 26 in MG-ADL Score in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations | -2.4 (-3.2 to -1.6) | -4.2 (-5.0 to -3.4) | -1.7 (-3.1 to -0.2) | -3.9 (-5.3 to -2.4) |
The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Score on a scale | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Change From Baseline in QMG Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations | -2.0 (-3.1 to -0.9) | -4.4 (-5.5 to -3.3) | -3.0 (-5.2 to -0.7) | -5.2 (-7.4 to -3.0) |
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included intravenous immunoglobulin (IVIg) and therapeutic plasma exchange (PLEX). Outcome measure is reported for the overall population.
| Participants | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in the Overall Study Population | 55 | 79 |
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included IVIg and PLEX. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Participants | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Percentage of Participants With Both ≥ 3-point Improvement in MG-ADL Score at Week 26 and no Use of Rescue Therapy Between Day 28 and Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations | 44 | 62 | 11 | 17 |
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. The protocol-allowed rescue therapy options included IVIg and PLEX. Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
The protocol-allowed rescue therapy options included corticosteroids, IVIg and PLEX. Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
The QMG score is a validated outcome comprised of 13 items: ocular (2 items), facial (1 item), bulbar (2 items), gross motor (6 items), axial (1 item), and respiratory (1 item). Each item has a possible score of between 0 and 3 points. The total score range is 0-39 points, with higher score indicating more severe disease. Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the overall population.
| Score on a scale | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Change From Baseline in Myasthenia Gravis Composite (MGC) Score at Week 26 in the Overall Study Population | -4.7 (-6.3 to -3.1) | -7.3 (-8.9 to -5.8) |
The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Score on a scale | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Change From Baseline in MGC Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations | -3.8 (-5.5 to -2.2) | -6.4 (-8.0 to -4.8) | -5.7 (-9.3 to -2.1) | -8.3 (-11.9 to -4.8) |
The MGC score consists of test items from MG-ADL score and the QMG score, with weighted response options. Scores range from 0-50, with higher scores indicating worse disease manifestations. Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
MG-ADL score is an 8-item questionnaire that focuses on relevant symptoms and functional performance of activities of daily living over the previous 7 days. The MG-ADL score assesses disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item) and gross motor or limb (2 items) impairment related to effects from MG. Each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL scores is 0-24. A higher score represents more severe disease Outcome measure is reported for the overall population.
| Score on a scale | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population | -2.2 (-3.0 to -1.5) | -4.2 (-4.9 to -3.4) |
MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome measure is reported for the overall population.
| Score on a scale | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Change From Baseline in Myasthenia Gravis Quality of Life-15, Revised (MGQOL-15r) Score at Week 26 in the Overall Study Population | -4.5 (-5.9 to -3.1) | -5.7 (-7.1 to -4.4) |
MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Score on a scale | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Change From Baseline in MGQOL-15r Score at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations | -3.6 (-5.0 to -2.2) | -4.9 (-6.3 to -3.5) | -5.1 (-8.5 to -1.7) | -6.5 (-9.7 to -3.3) |
MGQOL-15r score is a validated, patient-scored instrument, which measures the impact of MG on health-related quality of life (HRQoL). The 15 items in the questionnaire evaluate mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items) domains. Each item is rated on a 3-point scale ranging from 0 ("not at all") to 2 ("very much") based on their experience "over the past few weeks." Items scores are summed to generate a total score ranging from 0-45, with higher score indicating worse HRQoL. Outcome Measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. Participant rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse", Outcome measure is reported for the overall population.
| Participants | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Very Much Improved | 7 | 15 |
| Much Improved | 24 | 48 |
| Minimally Improved | 39 | 23 |
| No Change | 15 | 15 |
| Minimally Worse | 9 | 7 |
| Much Worse | 5 | 3 |
| Very Much Worse | 3 | 0 |
The self-report measure PGIC reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. Participants rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse". Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Participants | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab: Placebo | Anti-MuSK-Ab: Inebilizumab 300 mg |
|---|---|---|---|---|
| Very Much Improved | 4 | 12 | 3 | 3 |
| Much Improved | 17 | 36 | 7 | 12 |
| Minimally Improved | 32 | 20 | 7 | 3 |
| No Change | 13 | 14 | 2 | 1 |
| Minimally Worse | 8 | 3 | 1 | 4 |
| Much Worse | 5 | 2 | 0 | 1 |
| Very Much Worse | 2 | 0 | 1 | 0 |
The self-report measure PGIC score reflects a participant's belief about the efficacy of treatment. PGIC is a 7 point scale depicting a participant's rating of overall improvement. participants rate their change as "very much improved", "much improved", "minimally improved", "no change", "minimally worse", "much worse", or "very much worse". Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the overall population.
| Participants | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Percentage of Participants Experiencing Exacerbation by Week 26 in the Overall Study Population | 41 | 19 |
An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Participants | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Percentage of Participants Experiencing Exacerbation by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations | 30 | 16 | 11 | 3 |
An exacerbation was defined as one of the following: * Use of protocol defined rescue therapy, or * Myasthenic crisis, defined as worsening of myasthenic weakness requiring intubation or non-invasive ventilation to avoid intubation, except when these measures are employed during routine postoperative management, or * Significant symptomatic worsening to a score of 3 or a 2-point worsening from baseline on any one of the individual MG-ADL items other than double vision or eyelid droop. Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
MSE was defined as MG-ADL= 0 or 1. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK+ populations.
| Participants | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+:Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+:Inebilizumab 300 mg |
|---|---|---|---|---|
| Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 26 | 8 | 18 | 3 | 3 |
Outcome measure is reported for the overall population.
| Participants | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in the Overall Study Population | 77 | 83 |
Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Participants | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Percentage of Participants With Steroid Tapered to ≤ 5 mg/Day Steroid at Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations | 64 | 67 | 13 | 16 |
Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
Outcome measure is reported for the overall population.
| Participants | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Overall Study Population | 61 | 57 |
Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Participants | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Percentage of Participants Who Achieved ≥ 50% Steroid Reduction at Week 26 in the Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations | 49 | 47 | 12 | 10 |
Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
An AE is any untoward medical occurrence associated with the use of the IP, whether or not it is considered related. Clinically significant changes from baseline in clinical laboratory results, vital signs and ECGs were also reported as AEs. An AESI is an event of medical interest specific to the understanding of the IP and which may require close monitoring and collection of additional information. A SAE is considered "serious" if it results in any of the following outcomes: * Death; * A life-threatening AE. An event is considered "life-threatening" if its occurrence places the patient or subject at immediate risk of death; * Inpatient hospitalization or prolongation of existing hospitalization; * A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; * A congenital anomaly/birth defect; * May require medical or surgical intervention to prevent one of the outcomes listed in this definition.
| Participants | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| TEAEs | 70 | 77 | 17 | 19 |
| AESIs | 17 | 15 | 7 | 6 |
| SAEs | 15 | 8 | 1 | 2 |
Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported for the overall population.
| Participants | Overall: Placebo | Overall: Inebilizumab 300 mg |
|---|---|---|
| Percentage of Participants With Anti-drug Antibodies (ADA) by Week 26 in the Overall Study Population | 2 | 1 |
Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported in Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| Participants | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|---|---|
| Percentage of Participants With ADA by Week 26 in Anti-AChR-Ab+ and Anti-MuSK-Ab+ Populations | 1 | 1 | 1 | 0 |
Treatment emergent ADA were defined as ADA positive post-baseline only or boosted pre-existing ADA titer. Outcome measure is reported for the Anti-AChR-Ab+ population.
Results for this outcome have not been posted.
On inebilizumab dosing days, inebilizumab pharmacokinetic (PK) serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| day | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|
| Day 1 | 0.080 (0.066 to 0.10) | 0.081 (0.073 to 0.090) |
| Day 15 | 0.080 (0.0 to 17) | 0.080 (0.073 to 0.10) |
| Day 183 | 0.078 (0.052 to 0.12) | — |
On inebilizumab dosing days, inebilizumab PK serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| ug/mL | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|
| Day 1 | 108 ± 30 | 112 ± 23 |
| Day 15 | 120 ± 38 | 159 ± 19 |
| Day 183 | 107 ± 22 | — |
On inebilizumab dosing days, inebilizumab PK serum samples were collected pre-dose and approximately 15 minutes (± 5 minutes) after completion of the IP infusion. Outcome measure is reported for the Anti-AChR-Ab+ and Anti-MuSK-Ab+ populations.
| ug*day/mL | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Inebilizumab 300 mg |
|---|---|---|
| Day 1 | 848 ± 27 | 919 ± 25 |
| Day 15 | 1010 ± 40 | 1350 ± 18 |
| Day 183 | 1060 ± 24 | — |
Collected over For RCP mortality reporting: from randomization to the end of RCP or cutoff date; median (min, max) was 52.0 (2.4, 65.4) weeks. For RCP AE reporting: from Day 1 to the end of RCP or cutoff date; median (min, max) was 52.0 (2.4, 65.4) weeks. For OLP mortality and AE reporting: from the 1st dose of IP in OLP to the end of OLP or cutoff date; median (min, max) was 66.4 (0.1, 137.3) weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RCP: Placebo | 2/119 (1.7%) | 16/119 (13.4%) | 47/119 (39.5%) |
| RCP: Inebilizumab 300 mg | 1/119 (0.8%) | 10/119 (8.4%) | 53/119 (44.5%) |
| Optional OLP: Inebilizumab 300 mg | 1/178 (0.6%) | 14/178 (7.9%) | 40/178 (22.5%) |
| Event | RCP: Placebo | RCP: Inebilizumab 300 mg | Optional OLP: Inebilizumab 300 mg |
|---|---|---|---|
| COVID-19Infections and infestations | 3/119 | 2/119 | 1/178 |
| Myasthenia gravis crisisNervous system disorders | 3/119 | 2/119 | 0/178 |
| COVID-19 pneumoniaInfections and infestations | 1/119 | 2/119 | 3/178 |
| PneumoniaInfections and infestations | 0/119 | 0/119 | 3/178 |
| Acute myocardial infarctionCardiac disorders | 0/119 | 0/119 | 2/178 |
| Anaemia megaloblasticBlood and lymphatic system disorders | 1/119 | 0/119 | 0/178 |
| PancytopeniaBlood and lymphatic system disorders | 1/119 | 0/119 | 0/178 |
| Atrial fibrillationCardiac disorders | 1/119 | 0/119 | 0/178 |
| Cardio-respiratory arrestCardiac disorders | 1/119 | 0/119 | 0/178 |
| Coronary artery stenosisCardiac disorders | 1/119 | 0/119 | 0/178 |
| Event | RCP: Placebo | RCP: Inebilizumab 300 mg | Optional OLP: Inebilizumab 300 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 8/119 | 18/119 | 4/178 |
| COVID-19Infections and infestations | 9/119 | 12/119 | 10/178 |
| DiarrhoeaGastrointestinal disorders | 8/119 | 4/119 | 1/178 |
| NasopharyngitisInfections and infestations | 3/119 | 8/119 | 8/178 |
| Urinary tract infectionInfections and infestations | 3/119 | 8/119 | 2/178 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/119 | 5/119 | 1/178 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/119 | 8/119 | 8/178 |
| HypertensionVascular disorders | 8/119 | 2/119 | 2/178 |
| Upper respiratory tract infectionInfections and infestations | 7/119 | 4/119 | 11/178 |
| Infusion related reactionInjury, poisoning and procedural complications | 3/119 | 7/119 | 2/178 |
| Age, Categorical(Participants) | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 81 | 76 | 22 | 21 | 200 |
| >=65 years | 14 | 19 | 2 | 3 | 38 |
| Sex: Female, Male(Participants) | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg | Total |
|---|---|---|---|---|---|
| Female | 49 | 60 | 17 | 19 | 145 |
| Male | 46 | 35 | 7 | 5 | 93 |
| Ethnicity (NIH/OMB)(Participants) | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 8 | 3 | 1 | 18 |
| Not Hispanic or Latino | 89 | 86 | 21 | 23 | 219 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Anti-AChR-Ab+: Placebo | Anti-AChR-Ab+: Inebilizumab 300 mg | Anti-MuSK-Ab+: Placebo | Anti-MuSK-Ab+: Inebilizumab 300 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 40 | 31 | 15 | 15 | 101 |
| Other | 1 | 1 | 0 | 0 | 2 |
| Black or African American | 2 | 2 | 1 | 0 | 5 |
| White | 49 | 60 | 8 | 9 | 126 |
| Moore than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or not reported | 2 | 1 | 0 | 0 | 3 |
Showing the first 100 of 104 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2020 to primary completion in May 2024, 43 months.
Results were first posted in Mar 2026, 1 year 9 months after primary completion. A results delay was requested in Feb 2025.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 43 months is above that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inebilizumab